Risk of combining PPIs with thienopyridines: fact or fiction?

Lancet. 2009 Sep 19;374(9694):952-954. doi: 10.1016/S0140-6736(09)61562-2. Epub 2009 Aug 31.

Authors

Dirk Sibbing¹, Adnan Kastrati²

Affiliations

¹ Deutsches Herzzentrum München und 1 Medizinische Klinik rechts der Isar, Technische Universität München, 80636 Munich, Germany. Electronic address: dirk@sibbing.net.
² Deutsches Herzzentrum München und 1 Medizinische Klinik rechts der Isar, Technische Universität München, 80636 Munich, Germany.

PMID: 19726077
DOI: 10.1016/S0140-6736(09)61562-2

No abstract available

Publication types

Comment

MeSH terms

Biotransformation
Clopidogrel
Cytochrome P-450 Enzyme System / metabolism
Drug Interactions
Drug Therapy, Combination
Humans
Piperazines / adverse effects*
Piperazines / chemistry
Piperazines / metabolism
Platelet Aggregation Inhibitors / adverse effects*
Platelet Aggregation Inhibitors / chemistry
Platelet Aggregation Inhibitors / metabolism
Prasugrel Hydrochloride
Proton Pump Inhibitors / adverse effects*
Proton Pump Inhibitors / metabolism
Pyridines / adverse effects
Pyridines / chemistry
Pyridines / metabolism
Thiophenes / adverse effects*
Thiophenes / chemistry
Thiophenes / metabolism
Ticlopidine / adverse effects
Ticlopidine / analogs & derivatives*
Ticlopidine / chemistry
Ticlopidine / metabolism

Substances

Piperazines
Platelet Aggregation Inhibitors
Proton Pump Inhibitors
Pyridines
Thiophenes
thienopyridine
Cytochrome P-450 Enzyme System
Clopidogrel
Prasugrel Hydrochloride
Ticlopidine